Anthropic has launched physical biology laboratories and hired scientists to integrate real-world experiments into its drug discovery process. This initiative operates under the Claude Science platform, which debuted on June 30, 2026. The system utilizes over 60 scientific databases and models like Opus 4.8 to assist in genomics, proteomics, and computational biology.
The company is focusing its internal research on rare and neglected diseases that are often overlooked by traditional pharmaceutical firms due to economic constraints. Anthropic employs a feedback loop where AI generates molecular hypotheses, which are then validated by human scientists in wet labs. This process aims to refine model predictions through empirical testing.
In August 2026, the company reported that its models designed protein binders against 15 targets with a success rate of 22–35%, surpassing the industry standard of 10–15%. To further support research, Anthropic launched the Life Sciences Verification Program on September 17, 2026, offering grants and a protein design competition with $1 million in credits.
Early adopters of the platform include pharmaceutical companies Novo Nordisk and AstraZeneca, alongside various academic institutions. By moving into physical lab testing, Anthropic seeks to address the high costs and failure rates associated with drug development, aiming to make the research of rare conditions more economically viable.
